Geron
NASDAQ: GERN2 known investors
Find your way into Geron
Geron is a biopharmaceutical company focused on developing therapies for blood cancer. The company has over 30 years of experience in research and clinical development.
Founders & leadership
MD
Michael D. West
HS
Harout SemerjianinPresident & CEO
MJ
Michelle J. RobertsoninChief Financial OfficerMichelle J. Robertson is Executive Vice President, Chief Financial Officer, Treasurer and Interim Secretary at Geron, a biopharmaceutical company developing therapies for blood cancer. She brings extensive finance and operations experience in biotechnology, with expertise in financial planning, business process management, and acquisition integration.
JE
Joseph EidinEVP I CMO, Head of Research and DevelopmentJoseph Eid is Executive Vice President of Research and Development and Chief Medical Officer at Geron, a biopharmaceutical company developing therapies for blood cancer. He brings more than 20 years of industry experience in clinical development, medical affairs, regulatory strategy, and drug lifecycle management across large pharmaceutical and biotech companies.
AE
Ahmed ElNawawiinChief Commercial Officer (CCO)Ahmed ElNawawi held positions across pharmaceutical sales, product management, marketing, strategy, operations, and general management before becoming Executive Vice President and Chief Commercial Officer at Geron, a biopharmaceutical company developing therapies for blood cancer. He was born in Cairo, raised in Abu Dhabi, and has worked across multiple continents.
Investors · 2
In the news
Frequently asked questions
- What does Geron do?
- Geron is a biopharmaceutical company focused on developing therapies for blood cancer. The company has over 30 years of experience in research and clinical development.
- Who founded Geron?
- Geron was founded by Michael D. West.
- Who are Geron's investors?
- Geron's investors include BioBrit, New Enterprise Associates (NEA).